{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:30:02Z","timestamp":1789576202252,"version":"build-2803163510"},"reference-count":30,"publisher":"Oceanside Publications Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,9,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Mas-related G protein-coupled receptor X2 (MRGPRX2) and protease-activated receptor 2 (PAR2), are the main markers of nonhistaminergic pruriceptors. Elevated circulating MRGPRX2 levels have been reported in severe chronic spontaneous urticaria (CSU), whereas the\n role of serum PAR2 remains unclear.\n                    <jats:bold>Objective:<\/jats:bold>\n                    This study aimed to determine the differences in serum MRGPRX2 and PAR2 levels between patients with CSU and normal healthy controls (NC), and to evaluate their associations with disease severity and utility as biomarkers in\n CSU.\n                    <jats:bold>Methods:<\/jats:bold>\n                    The patients were stratified by the urticaria activity score over 7 days (UAS7) into three groups: severe (UAS7\u2009\u2265\u200928), moderate (16 \u2264 UAS7 &lt; 28), and mild (UAS7 &lt; 16). Serum samples from 60 patients with CSU and 30 NCs were screened\n for MRGPRX2 and PAR2 by using enzyme-linked immunosorbent assay.\n                    <jats:bold>Results:<\/jats:bold>\n                    The serum MRGPRX2 level was higher in the severe CSU group (0.31 \u00b1 0.12 ng\/mL) than in NCs (0.19 \u00b1 0.11 ng\/mL) (p\u2009&lt;\u20090.001) and in patients with mild-to-moderate CSU\n (0.24 \u00b1 0.08 ng\/mL) (p\u2009=\u20090.019). Similarly, the serum PAR2 level was also significantly higher in patients with severe CSU (0.38 [0.21\u20100.53] ng\/mL) compared with NCs (0.21 [0.11\u20100.27] ng\/mL) (p\u2009&lt;\u20090.001) and with patients with mild-to-moderate\n CSU (0.20 [0.15\u20100.27] ng\/mL) (p\u2009&lt;\u20090 .001). Both MRGPRX2 and PAR2 showed positive correlations with UAS7. PAR2 was negatively correlated with the basophil percentage, whereas MRGPRX2 showed no correlation with the basophil percentage. Logistic regression analysis identified\n serum MRGPRX2 levels \u2265 0.2375 ng\/mL (odds ratio 2.498; p\u2009=\u20090.002) and serum PAR2 levels \u2265 0.12 ng\/mL (odds ratio 1.901; p\u2009=\u20090.043) as two independent risk factors for CSU. In addition, serum PAR2 levels \u2265 0.271 ng\/mL (odds ratio 3.317; p\u2009=\u20090.002)\n were identified as an independent risk factor for severe CSU.\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    We suggest that serum MRGPRX2 and PAR2 are both biomarkers of disease severity and independent risk factors for CSU.\n                  <\/jats:p>","DOI":"10.2500\/aap.2026.47.260044","type":"journal-article","created":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T04:50:20Z","timestamp":1788583820000},"page":"e89-e97","source":"Crossref","is-referenced-by-count":1,"title":["Beyond immunoglobulin E (IgE): Novel roles of mas-related G protein-coupled receptor X2 (MRGPRX2) and protease-activated receptor 2 (PAR2) as nonhistaminergic pruriceptors in chronic spontaneous urticaria"],"prefix":"10.2500","volume":"47","author":[{"given":"Kun","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junlin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41572-022-00389-z","article-title":"Urticaria","volume":"8","author":"Kolkhir","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3389\/fimmu.2019.00627","article-title":"Autoimmune theories of chronic spontaneous urticaria","volume":"10","author":"Bracken","year":"2019","journal-title":"Front Immunol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s12016-021-08886-x","article-title":"Chronic urticaria: advances in understanding of the disease and clinical management","volume":"61","author":"He","year":"2021","journal-title":"Clin Rev Allergy Immunol"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.3390\/cells10051033","article-title":"Unlocking the non-IgE-mediated pseudo-allergic reaction puzzle with mas-related G-protein coupled receptor member X2 (MRGPRX2)","volume":"10","author":"Kumar","year":"2021","journal-title":"Cells"},{"key":"B5","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jaci.2020.08.027","article-title":"Mas-related G protein-coupled receptor X2 and its activators in dermatologic allergies","volume":"147","author":"K\u00fchn","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/jdv.20249","article-title":"Beyond the classic players: mas-related G protein-coupled receptor member X2 role in pruritus and skin diseases","volume":"39","author":"Kumar","year":"2025","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B7","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.3390\/cells10071759","article-title":"The role of coagulation and complement factors for mast cell activation in the pathogenesis of chronic spontaneous urticaria","volume":"10","author":"Yanase","year":"2021","journal-title":"Cells"},{"key":"B8","doi-asserted-by":"crossref","first-page":"627985","DOI":"10.3389\/fmed.2021.627985","article-title":"Involvement of neuro-immune interactions in pruritus with special focus on receptor expressions","volume":"8","author":"Ruppenstein","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"B10","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jaci.2013.12.1076","article-title":"Development and validation of the urticaria control test: a patient-reported outcome instrument for assessing urticaria control","volume":"133","author":"Weller","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3390\/ph16121707","article-title":"Targeting transient receptor potential (TRP) channels, mas-related G-protein-coupled receptors (MRGPRS), and protease-activated receptors (PARs) to relieve itch","volume":"16","author":"Tsagareli","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"B12","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4168\/aair.2021.13.3.498","article-title":"Elevated MRGPRX2 levels related to disease severity in patients with chronic spontaneous urticaria","volume":"13","author":"Cao","year":"2021","journal-title":"Allergy Asthma Immunol Res"},{"key":"B13","doi-asserted-by":"crossref","first-page":"10014","DOI":"10.1038\/s41598-025-94841-1","article-title":"Serum MRGPRX2 and substance P levels are biomarkers of disease activity rather than an antihistamine response in chronic spontaneous urticaria","volume":"15","author":"Cuc N","year":"2025","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.jaci.2025.03.007","article-title":"MRGPRX2 gain-of-function mutation drives enhanced mast cell reactivity in chronic spontaneous urticaria","volume":"156","author":"Ye","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1016\/j.jaci.2016.08.050","article-title":"Autoimmune chronic spontaneous urticaria: what we know and what we do not know","volume":"139","author":"Kolkhir","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.imlet.2023.11.008","article-title":"Mechanisms of histamine release from mast cells beyond the high affinity IgE receptor in severe chronic spontaneous urticaria","volume":"265","author":"Asero","year":"2024","journal-title":"Immunol Lett"},{"key":"B17","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1680574","DOI":"10.3389\/fimmu.2025.1680574","article-title":"Functional heterogeneity of mast cells in cutaneous inflammation: implications for precision medicine","volume":"16","author":"A","year":"2025","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1080\/1744666X.2019.1596800","article-title":"Recent advances in our understanding of mast cell activation - or should it be mast cell mediator disorders?","volume":"15","author":"Theoharides","year":"2019","journal-title":"Expert Rev Clin Immunol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1111\/all.13182","article-title":"Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: a systematic review","volume":"72","author":"Kolkhir","year":"2017","journal-title":"Allergy"},{"key":"B21","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1172\/JCI85538","article-title":"Different activation signals induce distinct mast cell degranulation strategies","volume":"126","author":"Gaudenzio","year":"2016","journal-title":"J Clin Invest"},{"key":"B22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1016\/j.jaci.2014.05.004","article-title":"Expression of mas-related gene X2 on mast cells is upregulated in the skin of patients with severe chronic urticaria","volume":"134","author":"Fujisawa","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s00210-016-1247-1","article-title":"Pharmacological treatment options for mast cell activation disease","volume":"389","author":"Molderings","year":"2016","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"3514","DOI":"10.1002\/art.22935","article-title":"Role of protease-activated receptor 2 in joint inflammation","volume":"56","author":"Lam","year":"2007","journal-title":"Arthritis Rheum"},{"key":"B25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1124\/jpet.111.187062","article-title":"Antagonism of protease-activated receptor 2 protects against experimental colitis","volume":"340","author":"Lohman","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"B26","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jaci.2023.05.004","article-title":"Basic mechanisms of itch","volume":"152","author":"Misery","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"crossref","first-page":"1448952","DOI":"10.3389\/fimmu.2024.1448952","article-title":"Protease-activated receptor 2 in inflammatory skin disease: current evidence and future perspectives","volume":"15","author":"Fan","year":"2024","journal-title":"Front Immunol"},{"key":"B28","doi-asserted-by":"crossref","first-page":"e2021386118","DOI":"10.1073\/pnas.2021386118","article-title":"Genetic priming of sensory neurons in mice that overexpress PAR2 enhances allergen responsiveness","volume":"118","author":"Braz","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"B29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa1215372","article-title":"Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria","volume":"368","author":"Maurer","year":"2013","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/all.15175","article-title":"Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: a one-year extension study","volume":"77","author":"Maurer","year":"2022","journal-title":"Allergy"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000005\/art00003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T04:32:38Z","timestamp":1789533158000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.260044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9,1]]}},"alternative-id":["1088-5412(20260901)47:5L.89;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.260044","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}